Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2001-07-02
2008-03-25
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S323000, C530S329000, C530S331000, C530S337000
Reexamination Certificate
active
07348310
ABSTRACT:
The invention relates to aplidine derivatives of the general formula:which are useful for the treatment of tumors.
REFERENCES:
patent: 4493796 (1985-01-01), Rinehart, Jr.
patent: 4670262 (1987-06-01), Battelli et al.
patent: 5294603 (1994-03-01), Rinehart
patent: 5462726 (1995-10-01), Lodge
patent: 5834586 (1998-11-01), Rinehart et al.
patent: 5883135 (1999-03-01), Gyory et al.
patent: 6030943 (2000-02-01), Crumb et al.
patent: 6034058 (2000-03-01), Rinehart et al.
patent: 6080877 (2000-06-01), Swindell et al.
patent: 6153731 (2000-11-01), Rinehart et al.
patent: 6156724 (2000-12-01), Rinehart et al.
patent: 6509315 (2003-01-01), Joullie et al.
patent: 6610699 (2003-08-01), Cavazza et al.
patent: 6710029 (2004-03-01), Rinehart et al.
patent: 6890904 (2005-05-01), Wallner et al.
patent: 7064105 (2006-06-01), Joullie et al.
patent: 0 048 149 (1982-03-01), None
patent: 0 393 883 (1990-10-01), None
patent: 2 102 322 (1997-07-01), None
patent: WO 91/04985 (1991-04-01), None
patent: WO 93/00362 (1993-01-01), None
patent: WO 98/17275 (1998-04-01), None
patent: WO 98/17302 (1998-04-01), None
patent: WO 99/42125 (1999-08-01), None
patent: WO 00/06134 (2000-02-01), None
patent: WO 00/71135 (2000-11-01), None
patent: WO 01/35974 (2001-05-01), None
patent: WO 01/76616 (2001-10-01), None
patent: WO 02/02596 (2002-01-01), None
patent: WO 02/30441 (2002-04-01), None
patent: WO 02/030441 (2002-04-01), None
patent: WO 03/033013 (2003-04-01), None
patent: WO 2004/080421 (2004-09-01), None
Mayer et al. Synthesis of New Didemnin B Analogs for Investigations of Structure/ Biological Activity Relationships. Journal of Organic Chemistry. 1994, vol. 59, No. 18, pp. 5192-5205.
Ady-Vago, N. et al., “L-Carnitine as a Protector Against Aplidine Induced Skeletal Muscle Toxicity”,Proceedings of the American Association for Cancer Research, vol. 42, pp. 545 (Mar. 2001).
Bergeron, Raymond J. et al., “Antineoplastic and Antiherpetic Activity of Spermidine Catecholamide Iron Chelators”,Biochemical and Biophysical Research Communications, vol. 121, No. 3, pp. 848-854 (1994).
Broggini, M. et al., “Aplidine Blocks VEGF Secretion and VEGF/VEGF-RI Autocrine Loop in a Human Leukemic Cell Line”,11thNCI-EORTC-AACR on New Drugs in Cancer Therapy, Amsterdam (2000), Abstract 21.
Chapa, A.M. et al., “Influence of Intravenous L-Carnitine Administration in Sheep Preceding an Oral Urea Drench1,2”,Journal of Animal Science, vol. 76, No. 11, pp. 2930-2937 (1998).
Depenbrock, H. et al., “In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumor cells and haematopoietic precursor cells”,British Journal of Cancer, vol. 78, No. 6, pp. 739-744 (1998).
Erba, E. et al., “Cell cycle phases perturbations induced by new natural marine compounds”,Annals of Oncology, vol. 7, Supplement 1, #283, pp. 82 (1996).
Faircloth, G. et al., “Aplidine (APL) is a novel marine-derived depsipeptide with in vivo antitumor activity”,Proceedings of the American Association for Cancer Research, vol. 39, #1551, pp. 227 (1998).
Faircloth, G. et al., “Dehydrodidemin B (DDB) a new marine derived anti-cancer agent (MDA) with activity against experimental tumor models” and “Biological activity of thiocoraline. A new depsipeptide from a marine micromonospora”,Annals of Oncology, vol. 7, Supplement 1, #111 and #112, pp. 34 (1996).
Faircloth, G. et al., “Preclinical characterization of Aplidine (APD), a new marine anticancer depsipeptice (MADEP)”,Proceedings of the American Association for Cancer Research, vol. 38, #692, pp. 103 (1997).
Faircloth, G. et al., “Preclinical development of aplidine, a novel marine-derived agent with potent antitumor activity”,Annals of Oncology, vol. 9, Supplement 2, #129, pp. 34 (1998).
Faircloth, G. et al., “Schedule-dependency of aplidine, a marine depsipeptide with antitumor activity”,Proceedings of the American Association for Cancer Research, vol. 40, #2612, pp. 394-395 (1999).
Geldof, Albert A. et al., “Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays”,Cancer Chemother. Pharmacol., vol. 44, pp. 312-318 (1999).
Genin, Michael J. et al., “Synthesis and Crystal Structure of a Peptidomimetic Containing the (R)-4, 4-Spiro Lactam Type-II β-Turn Mimic”,Journal of Organic Chemistry, vol. 58, No. 8, pp. 2334-2337 (1993).
Gomez-Fabre, P.M. et al., “Polamine contents of human breast cancer cells treated with the cytotoxic agents chlorpheniramine and dehydrodidemnin B”,Cancer Letters, vol. 113, Nos. 1, 2, pp. 141-144 (1997).
Jimeno et al., “A Correlation of Selective Antitumor Activities of the Marine-Derived Compound Aplidine Using Different Models”,10thNCI-EORTC-AACR Symposium on Molecular Targets and Cancer Therapeutics, Washington (1999), Abstract 311.
Jou, Gemma et al., “Total Synthesis of Dehydrodidemnin B. Use of Uronium and Phosphonium Salt Coupling Reagents in Peptide Synthesis in Solution”,Journal of Organic Chemistry, vol. 62, No. 2, pp. 354-366 (1997).
Lobo, C. et al., “Effect of Dehydrodidemnin B on Human Colon Carcinoma Cell Lines”,Anticancer Research, vol. 17, No. 1A, pp. 333-336 (1997).
Luber-Narod, J. et al., “In Vitro Safety Profile of Aplidine, A Marine Natural Product with Chemotherapeutic Potential”,Proceedings of the AACR, vol. 42, Abstract 374, Mar. 2001.
Mastbergen, S.C. et al., “Cytotoxicity and neurocytotoxicity of aplidine, a new marine anticancer agent evaluated using in vitro assays”,Annals of Oncology, vol. 9, Supplement 2, #131 (1998).
Montgomery, D.W. et al., “Didemnin B Alters the Specific Binding of Prolactin to Human Lymphocytes and Decreases the Circulating Level of Prolactin in Mice”,Federal Proceedings, vol. 44, No. 3, pp. 634, #1311 (1985).
Montgomery, David W. et al., “Didemnin B: A New Immunosuppressive Cyclic Peptide with Potent Activity In Vitro and In Vivo1”,Transplantation, vol. 40, No. 1, pp. 49-56 (1985).
Nuijen, B. et al., “Pharmaceutical development of anticancer agents derived from marine sources”,Anti-Cancer Drugs, vol. 11, pp. 793-811 (2000).
Raymond, Eric et al., “Preliminary Results of a Phase I and Pharmacokinetic Study of Aplidine Given as a 24-hour Infusion Every 2 Weeks in Patients With Solid Tumors and Non Hodgkin's Lymphomas”, Proceedings of the American Association for Cancer Research, vol. 41, #3886 (2000).
Rinehart, K., “Didemnin and its Biological Properties”,Escom., pp. 626-631 (1987).
Rinehart, Kenneth L. et al., “Biologically Active Peptides and Their Mass Spectra”,Pure and Applied Chemistry, vol. 54, No. 12, pp. 2409-2424 (1982).
Rinehart, Kenneth L. et al., “Didemnins and Tunichlorin: Novel Natural Products from the Marine Tunicate Trididemnum Solidum1”,Journal of Natural Products, vol. 51, No. 1, pp. 1-21 (1988).
Rinehart, Kenneth L. et al., “Total Synthesis of Didemnins A, B and C1,2”,Journal of the American Chemical Society, vol. 109, No. 22, pp. 6846-6848 (1987).
Rinehart, Kenneth L., Jr. et al., “Antiviral and antitumor compounds from tunicates1,2”Federation Proceedings, vol. 42, No. 1, pp. 87-90 (1983).
Rinehart, Kenneth L., Jr. et al., “Didemnins: Antiviral and Antitumor Depsipeptides from a Caribbean Tunicate”,Science, vol. 212, No. 4497, pp. 933-935 (1981).
Rinehart, Kenneth L., Jr. et al., “Structure of the Didemnins, Antiviral and Cytotoxic Depsipeptides from a Caribbean Tunicate1”,Journal of the American Chemistry Society, vol. 103, No. 7, pp. 1857-1859 (1981).
Sakai, Ryuichi et al., “Structure—Activity Relationships of the Didemnins1,2”,Journal of Medicinal Chemistry, vol. 39, No. 14, pp. 2819-2834 (1996).
Seebach, Dieter et al., “Alkylation of Amino Acids without Loss of Optical Activity: Pr
Cuevas Carmen
Cuevas Felix
Gallego Pilar
Manzanares Ignacio
Mendez Paloma
Fish & Richardson P.C.
Pharma Mar S.A.
Russel Jeffrey Edwin
LandOfFree
Synthetic methods for aplidine and new antitumoral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic methods for aplidine and new antitumoral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic methods for aplidine and new antitumoral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3972710